MNG500
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.279
- ESTROGEN_RESPONSE_EARLY+0.239
- PANCREAS_BETA_CELLS+0.239
- TGF_BETA_SIGNALING+0.217
- APOPTOSIS+0.155
- IL2_STAT5_SIGNALING+0.122
- INFLAMMATORY_RESPONSE+0.114
- UV_RESPONSE_DN+0.114
- PROTEIN_SECRETION+0.101
- KRAS_SIGNALING_DN+0.098
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.526
- MYC_TARGETS_V1-0.421
- MYC_TARGETS_V2-0.351
- UNFOLDED_PROTEIN_RESPONSE-0.329
- DNA_REPAIR-0.305
- ADIPOGENESIS-0.302
- WNT_BETA_CATENIN_SIGNALING-0.280
- FATTY_ACID_METABOLISM-0.278
- MTORC1_SIGNALING-0.244
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.222
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG608 | — | — | 0.810 |
| 2 | AUR-AER4-TTP1-A-1-0-R-A741-41 | — | D | 0.795 |
| 3 | C3N-02193 | — | cohortA1 | 0.784 |
| 4 | AUR-AFUM-TTP1-A-1-0-R-A741-41 | — | D | 0.783 |
| 5 | AUR-AFE4-TTP1-A-1-0-R-A741-41 | — | D | 0.778 |
| 6 | SRR8942991 | — | — | 0.775 |
| 7 | 5abd486a-6aed-4dcf-a2a2-2537af6cdd9c | — | — | 0.772 |
| 8 | 023160e4-1d9a-499c-9bfa-1b3aacf284f2 | — | — | 0.770 |
| 9 | AUR-AFKB-TTP1-A-10-0-R-A741-41 | — | D | 0.768 |
| 10 | SRR26320086 | — | — | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.279 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.239 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.239 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.217 | Inavolisib | — uncovered |
| APOPTOSIS | 0.155 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.122 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.114 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.114 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.101 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.098 | Remibrutinib | — uncovered |
| HYPOXIA | 0.081 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.066 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.053 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.041 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |